Roche Holding AG (RHHBY)
OTCMKTS · Delayed Price · Currency is USD
41.96
+0.94 (2.29%)
Sep 3, 2025, 4:01 PM EDT
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$773,189
Profits / Employee
$114,831
Market Cap
288.53B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
| Longduoduo Company | 49 |
Roche Holding AG News
- 6 hours ago - Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD) - GlobeNewsWire
- 18 hours ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 4 days ago - Alnylam (ALNY) Advances with Roche on Phase 3 Cardiovascular Trial for Zilebesiran - GuruFocus
- 4 days ago - Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for ... - GuruFocus
- 4 days ago - Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension - Business Wire
- 4 days ago - Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension - GlobeNewsWire
- 5 days ago - Analog Devices Chair & CEO Trades $5.09M In Company Stock - Benzinga
- 9 days ago - Roche's US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA - GlobeNewsWire